Objectives: To identify accessory mutations associated with high-level resistance to reverse transcriptase (RT) inhibitors in HIV-1 subtypes B and C.
Introduction
HIV-1 remains a major health problem worldwide. The introduction of highly active antiretroviral therapy (HAART) has greatly improved the life expectancy for those on treatment, and there has been good progress in rolling out treatment to the developing world. 1 However, drug resistance has been a considerable problem since treatment became available and most drug resistance research to date has been focused on HIV-1 subtype B, the most common subtype in the developed world. However, subtype C makes up .50% of HIV-1 infections worldwide, and resistance is likely to be an increasing issue in the developing world, particularly due to implementation of HAART in the absence of laboratory monitoring.
Some reports have described differences in the pathways to resistance between subtypes. For example, D30N in protease was rarely seen in subtype C-infected patients, while it was commonly seen in subtype B-infected patients treated with nelfinavir, 2,3 also the non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutation V106M is more common in subtype C than subtype B viruses. 4 Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) is mediated by combinations of thymidine analogue mutations (TAMs), with the relative prevalence of the type I TAM (M41L, L210W and T215Y) and type II TAM (D67N, K70R, T215F and K219E/Q) pathways varying between subtypes. For example, although the M41L and T215Y combination of TAMs is the most commonly seen in subtype B-infected patients treated with zidovudine, M41L is much less commonly seen in subtype C-infected patients. 5 The underlying mechanisms for the differences in resistance mutation pathways may either be due to differences in the genetic barrier, e.g. V106M, where only one transition is required in subtype C, while two transitions are required in other subtypes, 5, 6 or due to different fitness effects or structural constraints of specific mutations in the various subtype backgrounds. 7 -10 It has also been suggested that subtype-specific protein backbones can confer different in vitro resistance levels to some drugs in the wild-type (WT) form, 11 although clinical responses tend not to differ between subtypes. 12 Accessory mutations may occur during the development of resistance and these mutations can act either to increase drug resistance or to compensate for fitness loss caused by the presence of primary mutations. It has previously been shown in subtype B that accessory mutations are highly associated with the accumulation of TAMs and NNRTI resistance mutations. 13 -15 In this report we have extended this study to determine the accessory mutations associated with high-level resistance to NRTIs and NNRTIs in subtype C viruses and compared these with those present in subtype B. In addition, we have determined the effects of accessory mutations on drug susceptibility and infectivity in both subtype backgrounds.
Methods

Identification of accessory mutations
The UK HIV Drug Resistance Database collects information on the majority of genotypic resistance tests conducted in the UK as part of routine clinical care. 16 Bulk sequenced (sensitivity 15%-25%) resistance tests of the pol gene encoding codons 1 -400 of the reverse transcriptase (RT) gene were analysed. As a result of the variety of sequencing methods used by the different laboratories submitting resistance tests, not all samples provided data on all codons.
Subtype B and C HIV-infected patients, aged ≥16 years, who had at least one genotypic resistance test after starting antiretroviral therapy were identified from the database up to the end of 2007. For each test, the numbers of TAMs and NNRTI resistance mutations were determined [TAMs: M41L, D67any, K70R, L210W, T215any, K219any, 65-69 insertions and deletions; NNRTI resistance mutations: L100I, K103any (not R), V106M/A, V108I, Y181any, Y188any, G190any, P225H, M230L, P236L]. For patients tested more than once, 35% in subtype B and 22% in subtype C, the test with the greatest number of TAMs or NNRTI resistance mutations was selected for analysis. This resulted in the creation of four datasets of subtype B or C sequences containing either TAMs or NNRTI resistance mutations with one sequence per patient.
Statistical methods
For the purpose of this article, the most commonly occurring amino acid at a codon will be referred to as WT, and all other amino acids as mutations. For each subtype, one-way analysis of variance was used to test the association between the amino acid distribution and the accumulation of TAMs/NNRTI resistance mutations at each codon, with P values ,0.01 considered statistically significant. Accessory mutations were identified at codons where there was (i) a statistically significant association and (ii) the difference in the proportion of the WT amino acid between samples showing no TAMs/NNRTI resistance mutations and samples showing four or more TAMs or three or more NNRTI resistance mutations was .5%. Positions already established as drug resistance positions by the International AIDS Society (IAS) were not included in this analysis. 17 To compare the difference in the accessory mutations associated with the accumulation of TAMs/NNRTI resistance mutations between subtypes B and C, interaction tests using multinomial logistic regression were used to test the difference between the amino acid distribution and accumulation of TAMs/NNRTI resistance mutations at positions with the same WT amino acid in both subtypes. P values ,0.01 were considered statistically significant.
The strength of the association between accessory mutations identified for each separate subtype and specific known primary resistance mutations was expressed through risk ratios; the probability of an accessory mutation in samples in which the primary resistance mutation was present compared with samples in which it was absent. Interaction tests using log-binomial regression were conducted to see if the risk ratios differed across the specific set of TAMs/NNRTI resistance mutations, with P values ,0.01 considered statistically significant.
Plasmids and virus production
TAMs (M41L, D67N, L210W and T215Y) and accessory mutations (K43E, E44D and V118I) were introduced into gag-pol expression vectors by sitedirected mutagenesis using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). These mutations were introduced in an HIV-1 subtype B background in gag-pol expression vector p8.9NSX 18 and in an HIV-1 subtype C background in p8MJ4, a modified version of p8.9NSX where the subtype B gag-pol has been replaced by subtype C gag-pol derived from pMJ4 using restriction sites NotI and SmaI as described previously. 19 The presence and absence of mutations was verified by sequencing.
Pseudoviruses were produced by cotransfection of 293T cells with the gag-pol expression vector (p8.9NSX or p8MJ4) plus plasmid pMDG, encoding the vesicular stomatitis virus G protein, and plasmid pCSFLW, a retroviral expression vector that encodes the firefly luciferase reporter gene. 20 -22 The transfections were carried out in 6-well culture plates using 15 mL of polyethyleneimine (1 mg/mL). Cell monolayers were washed with PBS 6 h after transfection and 2 mL of fresh pre-warmed medium was added. Virus-containing supernatants were harvested by filtration through 0.45 mm filters 48 h after transfection.
Single-replication cycle drug susceptibility assay
The 50% inhibitory concentration (IC 50 ) of WT and mutant virus stocks was determined by measuring luciferase reporter gene expression levels after infection of 293T cells incubated in culture medium containing serial dilutions of drug. Virus stocks were produced as described above and luciferase activity was determined 48 h after infection using the SteadyGlo reporter assay (Promega). For each drug, 10 steps of 3-fold serial dilutions were used, with the highest concentration being 6 nM, 100 nM and 300 mM for zidovudine, stavudine and lamivudine, respectively. No cytotoxic effects were detected at these concentrations. Data were expressed relative to that of drug-free controls and IC 50 values were determined by linear regression analysis.
ELISA (Genetic Systems HIV-1 Ag EIA; Bio-Rad). The infectivity of mutant virus was expressed as a percentage of the relevant WT subtype B or subtype C control that was produced and titrated in parallel.
Antiretroviral drugs
The antiretroviral drugs zidovudine, stavudine and lamivudine were obtained through the NIH AIDS Research and Reference Program, Division of AIDS, NIAID, NIH.
Results
Accessory mutations associated with TAMs and NNRTI resistance in HIV-1 subtype B
Previously we identified 24 and 25 codons in subtype B HIV-1 RT where accessory mutations were associated with the accumulation of TAMs and NNRTI primary resistance mutations, respectively. 13 In this updated analysis, resistance tests from 5464 patients were available and we identified 31 and 26 codons where accessory mutations were associated with TAMs and NNRTI resistance, respectively, using the criteria described in the methods section [ Figure 1a and b, and Tables S1 and S2 (available as Supplementary data at JAC Online)]. The results excluded some previously identified accessory mutations, but also added new mutations. This is likely to be a result of an increase in the number of subtype B sequences analysed (from 3162 to 5464), especially in the region of RT encompassing codons 240-400. Some differences were also due to changes in the definition of drug resistance positions by the IAS, such as positions 44, 101 and 118.
Seven of the positions where accessory mutations were associated with the accumulation of both TAMs and NNRTI primary mutations (43, 44, 208, 218, 223 , 228 and 348), plus one associated with NNRTI mutations only (221), were non-polymorphic (defined as positions that exhibited ≥99% homogeneity in treatment-naive patients). Interestingly, six polymorphic positions were identified where the proportion of the WT amino acid increased with the accumulation of TAMs (83, 211, 245, 329, 366 and 400); the only polymorphic position where the proportion of WT amino acid increased with the accumulation of NNRTI primary mutations was position 83.
Accessory mutations associated with TAMs and NNRTI resistance in HIV-1 subtype C Resistance tests from 1920 patients infected with HIV-1 subtype C were available for analysis. A total of 18 and 13 codons were identified where accessory mutations were associated with the accumulation of TAMs and NNRTI primary mutations, respectively [ Figure 1a and b, and Tables S3 and S4 (available as Supple Comparison of the accessory mutations associated with the accumulation of TAMs/NNRTI resistance between subtypes B and C at codons with the same WT amino acid for both subtypes Amino acid changes at positions 43, 118, 135 and 326 were differentially associated with the accumulation of TAMs in subtypes B and C (Table 1) . At position 43 the dominant change was from WT amino acid K to E; however, this change was greatest in subtype B patients, where the decrease in the proportion of amino acid K between 0 and 4+ TAMs was 27.0%, compared with only 2.5% for subtype C (P,0.001; multinomial logistic regression). At positions 118 and 135, accessory mutations were associated with the accumulation of TAMs in subtypes B and C separately; however, the specific amino acid changes were different between the subtypes. At position 118, the change from V to I was more pronounced in subtype B than C (P,0.001), and vice versa at position 135, where the change from I to T was more pronounced in subtype C (P,0.001). At position 326 the changes in the amino acid distribution were in opposite directions in the two subtypes, with a statistically significant decrease of 7.6% in the proportion of WT amino acid I between 0 and 4+ TAMs in subtype C compared with an increase of 2.6% in subtype B, which did not reach statistical significance.
Amino acid changes at positions 43 and 68 were differentially associated with the accumulation of NNRTI mutations in subtypes B and C ( Table 2) . As for the analysis looking at the accumulation of TAMs, the dominant change from WT amino acid K to E at position 43 was greatest in subtype B patients, where the decrease in the proportion of amino acid K between 0 and 3+ NNRTI primary mutations was 10.2% compared with only 0.5% for subtype C (P ¼ 0.002). Accessory mutations were associated with the accumulation of NNRTI primary mutations in subtypes B and C separately at position 68, where the change from S to G was more pronounced in subtype C than B (10.3% versus 5.2%; P ¼ 0.003).
Association of accessory mutations with specific TAM resistance pathways and NNRTI primary mutations in subtypes B and C To investigate if certain accessory mutations were associated with a specific TAM resistance pathway and/or a specific NNRTI mutation in subtypes B and C, we determined the accessory mutations for which the risk ratio was significantly different across the primary resistance mutations in both subtypes separately. In subtype B, accessory mutations at positions 43, 44, 98, 118, 208 and 223 were mostly associated with the previously described type I TAM resistance pathway (M41L, L210W and T215Y), 23 whereas mutations at positions 60 and 218 were associated with the type II TAM resistance pathway (D67N, K70R, T215F and K219E/Q) ( Figure 2a) . Accessory mutations at positions 122, 196, 203 and 228 were associated with both type I and II TAM resistance pathways (Figure 2a ). For NNRTI mutations, the probability of an accessory mutation occurring at positions 43, 179 and 221 was significantly higher in the presence of the Y181I mutation in subtype B (Figure 2b ). The accessory mutations at positions 43 and 221 were also strongly associated with Y188L and Y181C, respectively. In addition, several NNRTI 1600 1918 1918 1918 1918 1918 1918 1916 1916 1916 1911 1911 1911 1910 1906 1900 1604 1920 1920 1920 1920 1920 1920 1920 1920 1918 1918 1918 1913 1913 1912 1912 1903 Continued mutations were associated with the probability of accessory mutations occurring at positions 118, 203, 208, 228 and 284. In subtype C, accessory mutations at positions 44, 118 and 208 were most strongly associated with the type I TAM resistance pathway, whereas mutations at position 203 were associated with the type II TAM pathway (Figure 2c ). Position 179 was the only position where the risk ratio was significantly different across the particular NNRTI mutations analysed; accessory mutations at this position were most strongly associated with V106M and Y181I (Figure 2d ).
Effect of accessory mutations on drug susceptibility and viral infectivity
To further elucidate the role of accessory mutations in the development of drug resistance, we investigated the effects of particular accessory mutations on drug susceptibility using a subtype-specific single-replication cycle phenotypic assay. We analysed the accessory mutations K43E, E44D and V118I that have the same WT amino acid in subtypes B and C and were strongly and/or differentially associated with the type I TAM resistance pathway in both subtypes. Site-directed mutagenesis was used to introduce the accessory mutations into subtype B and C recombinant vectors, either alone or in combination with an increasing number of type I TAMs (Figure 3a) . We tested the susceptibility of the recombinant viruses to the thymidine analogues zidovudine and stavudine. Viruses expressing the accessory mutations alone or in combination with one (M41L), two (M41L +T215Y) or four (M41L +D67N + L210W+ T215Y) TAMs exhibited zidovudine and stavudine IC 50 values that were similar to WT virus or viruses expressing TAMs without the accessory mutations, respectively (Figure 3b and c) . The only exception Derived from approximately 10000 and 4000 samples for subtype B and subtype C, respectively, recorded within the UK HIV resistance database. c Multinomial logistic regression was used to test the difference between the association between amino acid distribution and accumulation of TAMs in subtypes B and C at codons with the same WT amino acid for both subtypes. Subtype-specific accessory mutations in HIV-1 RT Derived from approximately 10000 and 4000 samples for subtype B and subtype C, respectively, recorded within the UK HIV resistance database. c Multinomial logistic regression was used to test the difference between the association between amino acid distribution and accumulation of TAMs in subtypes B and C at codons with the same WT amino acid for both subtypes. Subtype-specific accessory mutations in HIV-1 RT was the addition of the accessory mutation E44D to two TAMs (M41L +T215Y), which resulted in a statistically significant, but modest, 2-fold decrease in susceptibility to zidovudine in subtype B (Figure 3b) . The IC 50 values of viruses with four TAMs using zidovudine were above the limit of our assay; therefore, we could not arrive at any conclusions on the effect of the accessory mutations in these viruses.
We next examined the role of the accessory mutations on the infectivity of the recombinant viruses in a single-round infectivity assay. This showed that the presence of the TAM M41L or accessory mutation K43E alone significantly decreased viral infectivity compared with that of the WT virus (Figure 3d ). This effect was more pronounced in subtype B viruses, where the presence of M41L or K43E reduced the level of infectivity to 1% or 3%, respectively, of the WT subtype B control. In contrast, subtype C viruses containing the M41L or K43E amino acid changes exhibited 53% or 40% infectivity, respectively, of the WT subtype C control. However, this defect in infectivity was fully compensated in the presence of additional TAMs or accessory mutations. In addition, the combination of M41L and E44D significantly reduced the infectivity of subtype C virus to 30% of the WT subtype C virus, but this combination had no effect in subtype B. Taken together, these data suggest a subtype-specific effect on infectivity levels of some of the accessory mutations we tested, when present alone or in combination with a single TAM. However, the accessory mutations had minimal or no effect on susceptibility to zidovudine and stavudine in a singlecycle drug susceptibility assay.
Association of accessory mutations K43E, E44D and V118I with other NRTI resistance mutations
It has been reported that E44D and V118I could be involved in the emergence of virus resistant to both zidovudine and lamivudine in the absence of M184V. 24, 25 We, therefore, investigated the association of E44D and V118I with the accumulation of TAMs in the presence or absence of M184V by measuring the frequency of association of these mutations in our dataset. Overall, the analysis of the subtype B and C datasets showed an increase in the frequency of association of both accessory mutations with an increasing number of TAMs; however, there was no difference in the frequencies of E44D and V118I in the presence or absence of M184V in both subtypes (Tables 3 and 4) . We further determined the effect of E44D or V118I alone or in combination with an increasing number of TAMs on the susceptibility to lamivudine using recombinant subtype B viruses. The presence of the accessory mutations alone or in combination with one TAM (M41L) or two TAMs (M41L and T215Y) had no significant 43  118  179  203  208  221  228  284   K101I  K103N  V106M  V106A  V108I  Y181I  Y181C  Y188C  Y188H  Y188L  G190A  G190S  P225H  M230L  0.01   0.1   1   10   100   179   K101I  K103N  V106M  V106A  V108I  Y181I  Y181C  Y188C  Y188L  G190A  M230L  Risk ratio (log scale) Risk ratio (log scale)   M41L  D67N  K70R  L210W  T215F  T215Y  K219E  K219Q   M41L  D67N  K70R  L210W  T215F  T215Y  K219E  K219Q (a) (c)
Amino acid position of accessory mutation Amino acid position of accessory mutation effect on the susceptibility to lamivudine (Figure 4) . The presence of four TAMs (M41L +D67N + L210W+ T215Y) resulted in a decrease in the susceptibility to lamivudine by 5-fold, which was less than that observed with M184V. However, the effect of four TAMs on lamivudine susceptibility was not significantly affected by the additional presence of E44D or V118I (Figure 4) . It has also been recently shown that K43E is associated with the emergence of a novel NRTI resistance mutation E40F. 26 To investigate if there was an association between the two mutations we determined their frequencies in our datasets. The analysis showed that the E40F mutation was present at a frequency of 0.4% (22 of 5464 sequences) in subtype B (Table 5) , which was similar to that observed in a previous study. 26 Of the 22 sequences, 18 of them also contained the K43E mutation. In contrast, of the 1926 subtype C sequences analysed, none contained the E40F mutation, whereas 11 had the K43E mutation.
Discussion
Accessory drug resistance mutations in HIV-1 RT can develop in less conserved regions or polymorphic sites; therefore, we hypothesized that subtype-specific differences are likely to exist. In this study we undertook an analysis of accessory mutations associated with the accumulation of TAMs and NNRTI mutations in HIV-1 subtypes B and C. This extends our previous description of accessory mutations in subtype B only. 13 Likewise, the datasets used in this study encompass RT codons 1 -400, in contrast to other studies that have reported data on the first 240 codons of RT only. 27 -30 Thus, our analysis includes the HIV-1 RT thumb and connection subdomains (positions 241-424), which have recently been linked with the development of drug resistance to RT inhibitors. 31 -34 In particular, some of the mutations in the connection subdomain, such as N348I and A400T, have been shown to significantly affect the susceptibility of HIV-1 to different RT inhibitors. 32, 34, 35 In this study we identified significant subtype-specific differences in accessory mutations associated with the accumulation of TAMs and NNRTI mutations. We observed differences in (i) the development of accessory mutations at positions with the same WT amino acid in both subtypes, (ii) the association of particular accessory mutations with specific primary drug resistance mutations or pathways, and (iii) the overall number of accessory mutations identified in each subtype. Subtype-specific differences in drug-associated mutations have in part been postulated to be due to polymorphisms. Our data show that accessory mutations occurred at 10 positions exhibiting ≥99% homogeneity in treatment-naive patients. Of these, mutations at positions 43 and 284 were associated with the accumulation of TAMs in subtype B. On the other hand, non-polymorphic positions 43, 208, 223 and 348 in subtype B and 68 in subtype C were associated with the accumulation of NNRTI mutations. Taken together, these differences suggest that the subtype-specific background sequence plays a significant role in the type and number of accessory mutations that develop in association with primary resistance mutations. This is consistent with our data showing that the presence of a single TAM (M41L) or accessory mutation (K43E) resulted in more dramatic effects on the infectivity of subtype B than C virus; 1% versus 53% or 3% versus 40%, respectively, relative to WT viruses. These findings are also further corroborated by other studies that have shown a greater impact on replicative capacity of subtype B than C viruses in the presence of single or double TAM mutations (D67N, K70R or M41L+T215Y), as well as an increase in the replicative capacity of subtype C, but not B, viruses in the presence of triple type I TAM mutations (M41L + L210W+ T215Y). 7, 36 However, it is also possible that the differences in the type and number of accessory mutations between the two subtypes could be influenced by the frequency and patterns of TAM pathway and NNRTI resistance mutations, which have been reported to vary between the two subtypes. It has been shown that the type I TAM pathway is more frequently observed than the type II TAM pathway in subtype B, whereas another study showed preferential development of mixtures of type I and II TAM pathway mutations in patients infected with subtype C. 5, 36 The analysis of the updated subtype B dataset excluded two and six previously identified accessory mutations, but identified nine and seven new accessory mutations associated with TAMs and NNRTI mutations, respectively. This difference between the two analyses is due in part to changes in the definition of drug resistance positions by the IAS (i.e. positions 44, 101 and 118 were previously classified as resistance mutations), as well as an increase in the number of sequences available for analysis, which nearly doubled from 3162 to .5463. Additionally, the difference could be due to genetic drift or a change in treatment regimens used over time. The development of accessory mutations in antiretroviral therapy-experienced patients has been shown to significantly differ depending on the type of RT inhibitor regimen used. 31,37 -39 Treatment data were available for 77% and 68% of the patients in the original and updated analyses, respectively. The biggest change between the two datasets was a decrease in patients exposed to both stavudine and zidovudine from 56% in the original analysis to 45% in the updated analysis, which could possibly account for some of the differences.
Interestingly, our analysis also shows a considerable overlap in the positions identified to be associated with TAMs and NNRTI mutations, particularly in subtype B. Twenty of the 36 accessory mutations identified in subtype B (56%) and 8 of the 23 accessory mutations identified in subtype C (35%) were associated with both TAMs and NNRTI mutations. This either suggests a similarity in the structural and/or mechanistic changes induced in RT by TAMs and NNRTI mutations in each subtype, which are then compensated for by the same accessory mutation(s), or it could be due to a piggyback effect of the accessory mutation(s) since all of the patients were subjected to NRTI backbone-based regimens.
Although our data clearly show significant subtype-specific differences in the development of accessory mutations associated with TAMs and NNRTI mutations and their possible effect on infectivity, we find that the accessory mutations do not significantly influence viral susceptibility to RT inhibitors. This finding is consistent with several studies comparing the development of drug resistance in B and non-B subtypes that have reported no significant subtype-specific differences in the emergence of primary drug resistance or the virological response to antiretroviral therapy. 40 -43 Several biochemical studies suggest that the effect of the accessory mutations on replicative fitness could be due in part to their effects on RT activity. 44, 45 Therefore, it would be interesting to determine the biochemical effects on RT activity of the different combinations of accessory mutations and primary drug resistance mutations identified in this study in both subtypes.
On the other hand, our data suggest that the emergence of the novel E40F resistance mutation could be subtype-specific. It is also worth noting that other studies have reported significant differences in the rate of accumulation of drug resistance mutations or virological response to combination antiretroviral therapy between subtype B and non-B subtypes. 46, 47 One reason for the contradictory conclusions could be due to differences in combination antiretroviral therapy regimens. Therapies containing unboosted protease inhibitors (PIs) were shown to account for the largest differences in virological response between subtype B and non-B subtypes. 47 Similarly, the rate of accumulation of resistance mutations was shown to be significantly different for PIs only between subtypes B and C. 46 It is also possible that differences in the genetic barrier for particular codon positions between subtypes, as well as other confounding factors, such as study sample size, ethnicity of the study population, cultural characteristics and transmission risk groups, could contribute to the disparities between studies. 6, 48 In summary, our data-in conjunction with other studiessuggest that despite significant subtype-specific differences in the development of accessory mutations associated with TAMs and NNRTI mutations, these do not seem to significantly affect drug susceptibility, but could play a role in restoring viral replication fitness. Nonetheless, the presence of these mutations, especially at non-polymorphic positions, could possibly serve as biomarkers for surveillance of transmitted drug resistance, particularly if they do not significantly affect viral infectivity, and, therefore, could potentially have longer half-lives compared with some primary drug resistance mutations.
